David Fink, MD
Obstetrics & Gynecology · Newark, DENPI 1255338844
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $508 and has fallen 68.2% since, to $162 in 2025.
Across 139 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$505
- Amgen$199
- Astellas Pharma US Inc$181
- Evofem Biosciences, Inc.$178
- Therapeuticsmd, Inc.$158
- Mylan Pharmaceuticals Inc.$128
- plus $968 from 18 others
What the payments were for
- Food & beverage$2,19695%
- Education$1225%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $505 |
| Amgen | 12 | $199 |
| Astellas Pharma US Inc | 11 | $181 |
| Evofem Biosciences, Inc. | 18 | $178 |
| Therapeuticsmd, Inc. | 8 | $158 |
| Mylan Pharmaceuticals Inc. | 7 | $128 |
| Sumitomo Pharma America, Inc. | 6 | $110 |
| Myovant Sciences Inc. | 6 | $108 |
| Sage Therapeutics, LLC | 4 | $89 |
| AMAG Pharmaceuticals, Inc. | 5 | $85 |
| Mission Pharmacal Company | 6 | $83 |
| Exact Sciences | 3 | $68 |
| Exeltis, USA Inc. | 3 | $57 |
| Millicent US Inc | 1 | $53 |
| Agile Therapeutics, Inc. | 3 | $53 |
| Avion Pharmaceuticals | 3 | $51 |
| Daiichi Sankyo Inc. | 3 | $49 |
| Covidien LP | 2 | $39 |
| Radius Health, Inc. | 2 | $33 |
| Shield Therapeutics Inc | 1 | $24 |
| Lupin Inc. | 1 | $24 |
| Bayer | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $13 |
| Coopersurgical, Inc. | 1 | $12 |
How this compares
$2,318 in reported general payments places this provider in the 80th percentile of 139 obstetrics & gynecology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Norethindrone Acetate | 25 | $2,026 |
| Estradiol | 26 | $1,606 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Newark
- Anthony BellNewark$17K
- Richard DermanNewark$14K
- Gordon OstrumNewark$4K
- Colleen DeturkNewark$4K
- Patricia CiranniNewark$3K
- Michelle PacisNewark$3K
- Gregory DemeoNewark$3K
- Jose PicazoNewark$2K
- Stefanie MarshallNewark$2K
- Faith BroschNewark$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.